Established and emerging biomarkers approaches in Urothelial carcinoma.

Journal: Expert review of anticancer therapy
Published Date: Aug 5, 2025

Abstract

INTRODUCTION: Urothelial carcinoma (UC) is marked by significant molecular heterogeneity and this complexity challenges precision medicine. Recent advances have improved biomarker development for UC diagnosis, prognosis and treatment.

Authors

  • Sara Coca Membribes
    Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Elizabeth Nally
    Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Francesca Jackson-Spence
    Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Catherine Graham
    Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Salina Lalwani
    Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Bernadett Szabados
    Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
  • Thomas Powles
    Barts Cancer Institute, Queen Mary University of London, London, UK.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals